6533b853fe1ef96bd12acbe0

RESEARCH PRODUCT

Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid

Manuel Díaz-llopisA. Vieira-barrosM.j. Roig-revertR. Dolz-marcoJ. BadalL. AmselemRoberto Gallego-pinazoM. Cuesta-lasso

subject

MaleDegeneracion macular asociada a la edad no neovascularVisual acuityTriamcinolone acetonidegenetic structuresFluido subretinianoAngiogenesis InhibitorsFundus (eye)Triamcinolone0302 clinical medicineDegeneración macular asociada a la edad no neovascular Fluido intrarretiniano Fluido subretiniano Intraretinal fluid Intravitreal therapies Non-neovascular age related macular degeneration Spectral domain optical coherence tomography Subretinal fluid Terapias intravítreas Tomografía de coherencia óptica de dominio espectralFluorescein AngiographyTomografia de coherencia optica de dominio espectralAged 80 and overmedicine.diagnostic_testSubretinal FluidExudates and TransudatesGeneral MedicineFluorescein angiographyFluido intrarretinianoBevacizumabTreatment Outcomemedicine.anatomical_structureIntravitreal InjectionsFemalemedicine.symptomIntravitreal therapiesTomography Optical Coherencemedicine.drugSubretinal fluidmedicine.medical_specialtyBevacizumabRetinal DrusenRetinaSpectral domain optical coherence tomography03 medical and health sciencesNon-neovascular age related macular degenerationRanibizumabOphthalmologymedicineHumansAgedRetinabusiness.industryMacular degenerationmedicine.diseaseTerapias intravitreaseye diseasesSurgeryWet Macular Degeneration030221 ophthalmology & optometryIntraretinal fluidsense organsRanibizumabbusiness030217 neurology & neurosurgery

description

OBJECTIVE: To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS: A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography. RESULTS: The study included 14 eyes from 13 patients with a mean age of 72.64 years and a mean follow-up of 80.5 weeks. Intraretinal fluid was observed in 6 eyes (42.9%), while subretinal fluid was shown in 8 eyes (57.1%), with high density in 4 eyes (28.5%), and low density in 4 eyes (28.5%). Snellen best-corrected visual acuity improved from 0.37 at baseline to 0.56 at the final visit (P=.002). Central subfield thickness (microns) significantly decreased (P<.001) from 291.0 at baseline to 228.9 at the final visit. Eight eyes received ranibizumab, 5eyes received bevacizumab, and one case received triamcinolone. CONCLUSIONS: Cases of atrophic AMD may present with subretinal or intraretinal fluid in the absence Neovascularisation. Further studies are required to analyse the value of this finding as a risk factor of developing advanced forms of AMD, as well as the efficacy of intravitreal therapies.

yearjournalcountryeditionlanguage
2017-01-01Archivos de la Sociedad Española de Oftalmología (English Edition)
https://doi.org/10.1016/j.oftale.2017.01.001